Dexcom Share Price Today
(NASDAQ: DXCM)

Name: Dexcom Share Price Today (NASDAQ: DXCM) - Dexcom Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Dexcom share price is $86.83 & ₹7,522.95 as on 1 Feb 2025, 2.30 'hrs' IST

$86.83

▲

-0.79

(-0.9%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Dexcom share price in Dollar and Rupees. Guide to invest in Dexcom stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Dexcom, along with analyst recommendations, forecasts, and comprehensive financials.

Dexcom share price movements

Today's Low: $86.59
Today's High: $88.16
$86.83
0.28%
Downside
Day's Volatility :1.78%
Upside
1.51%
52 Weeks Low: $62.34
52 Weeks High: $142.00
$86.83
28.2%
Downside
52 Weeks Volatility :56.1%
Upside
38.85%

Dexcom (DXCM) Returns

Period	Dexcom, Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	24.58%	-0.6%	7.6%
6 Months	19.88%	-2.8%	14.2%
1 Year	-28.22%	3.3%	27.8%
3 Years	-20.28%	11.6%	36.8%

Dexcom (DXCM) Key Statistics

in dollars & INR

Previous Close	$87.62
Open	$86.87
Today's High	$88.16
Today's Low	$86.59
Market Capitalization	$33.9B
Today's Volume	$2.3M
52 Week High	$142.0
52 Week Low	$62.34
Revenue TTM	$4.0B
EBITDA	$840.4M
Earnings Per Share (EPS)	$1.65
PE Ratio	52.62
Profit Margin	17.22%
Quarterly Earnings Growth YOY	0.16%
Return On Equity TTM	32.06%

How to invest in Dexcom Stock (DXCM) from India?

It is very easy for Indian residents to invest directly in Dexcom from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Dexcom stock in both Indian Rupees (INR) and US Dollars (USD). Search for Dexcom or DXCM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Dexcom or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Dexcom shares which would translate to 0.010 fractional shares of Dexcom as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Dexcom, in just a few clicks!

Returns in Dexcom (DXCM) for Indian investors in Rupees

The Dexcom stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Dexcom investment value today

Current value as on today

₹76,343

Returns

₹23,657

(-23.66%)

Returns from Dexcom Stock

₹28,216 (-28.22%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Dexcom (DXCM)

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Dexcom Stock from India on INDmoney has increased by 4% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Dexcom Stock (DXCM Ticker)

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	5086	0.00	0.19%
Motilal Oswal S&P 500 Index Fund Direct Growth	3369	7.68	0.06%

Global Institutional Holdings in Dexcom

Vanguard Group Inc
12.14%
BlackRock Inc
8.97%
Capital Research Global Investors
4.60%
State Street Corp
4.27%
Baillie Gifford & Co Limited.
3.84%
Sands Capital Management, LLC
2.64%

Analyst Recommendation on Dexcom

Buy

86%Buy

13%Hold

0%Sell

Based on 30 Wall street analysts offering stock ratings for Dexcom(by analysts ranked 0 to 5 stars)

Based on 30 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Dexcom Stock (DXCM)

What analysts predicted

Upside of 10.86%

Target:

$96.26

Current:

$86.83

Insights on Dexcom Stock (Ticker Symbol: DXCM)

Price Movement
In the last 1 month, DXCM stock has moved up by 11.6%
Decreasing Revenue
Dexcom, Inc. has experienced a decline in revenue over the last two quarters, dropping from $1.00 billion to $994.2 million. This represents an average decrease of 1.0% per quarter.
Decreasing Net Profit
Dexcom, Inc. has seen a decline in its net profit over the last four quarters, dropping from $256.3 million to $134.6 million. This represents an average decrease of 17.0% in net profit each quarter.
DXCM vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 57.9% return, outperforming this stock by 87.1%
DXCM vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 135.3% return, outperforming this stock by 155.5%
Price to Sales
Currently, investors are willing to pay $8.6 for every $1 of sales generated by Dexcom, Inc. This is lower than the $9.5 investors are willing to pay for every $1 of sales from Boston Scientific Corp. This suggests that Dexcom has a relatively lower valuation based on its sales compared to Boston Scientific.

DXCM Dexcom Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.0B	↑ 43.58%
Net Income	$-127.1M	↑ 153.19%
Net Profit Margin	-12.32%	↓ 5.33%

	FY19	Y/Y Change
Revenue	$1.5B	↑ 43.08%
Net Income	$101.1M	↓ 179.54%
Net Profit Margin	6.85%	↑ 19.17%

	FY20	Y/Y Change
Revenue	$1.9B	↑ 30.54%
Net Income	$493.6M	↑ 388.23%
Net Profit Margin	25.62%	↑ 18.77%

	FY21	Y/Y Change
Revenue	$2.4B	↑ 27.08%
Net Income	$154.7M	↓ 68.66%
Net Profit Margin	6.32%	↓ 19.3%

	FY22	Y/Y Change
Revenue	$2.9B	↑ 18.84%
Net Income	$341.2M	↑ 120.56%
Net Profit Margin	11.73%	↑ 5.41%

	FY23	Y/Y Change
Revenue	$3.6B	↑ 24.49%
Net Income	$541.5M	↑ 58.7%
Net Profit Margin	14.95%	↑ 3.22%

	Q2 FY23	Q/Q Change
Revenue	$871.3M	↑ 17.51%
Net Income	$115.9M	↑ 138.48%
Net Profit Margin	13.3%	↑ 6.75%

	Q3 FY23	Q/Q Change
Revenue	$975.0M	↑ 11.9%
Net Income	$120.7M	↑ 4.14%
Net Profit Margin	12.38%	↓ 0.92%

	Q4 FY23	Q/Q Change
Revenue	$1.0B	↑ 6.1%
Net Income	$256.3M	↑ 112.34%
Net Profit Margin	24.78%	↑ 12.4%

	Q1 FY24	Q/Q Change
Revenue	$921.0M	↓ 10.97%
Net Income	$146.4M	↓ 42.88%
Net Profit Margin	15.9%	↓ 8.88%

	Q2 FY24	Q/Q Change
Revenue	$1.0B	↑ 9.04%
Net Income	$143.5M	↓ 1.98%
Net Profit Margin	14.29%	↓ 1.61%

	Q3 FY24	Q/Q Change
Revenue	$994.2M	↓ 1.01%
Net Income	$134.6M	↓ 6.2%
Net Profit Margin	13.54%	↓ 0.75%

	FY18	Y/Y Change
Profit	$663.9M	↑ 34.91%

	FY19	Y/Y Change
Profit	$931.5M	↑ 40.31%

	FY20	Y/Y Change
Profit	$1.3B	↑ 37.42%

	FY21	Y/Y Change
Profit	$1.7B	↑ 31.28%

	FY22	Y/Y Change
Profit	$1.9B	↑ 12.06%

	FY23	Y/Y Change
Profit	$2.3B	↑ 21.55%

	Q2 FY23	Q/Q Change
Profit	$546.4M	↑ 18.12%

	Q3 FY23	Q/Q Change
Profit	$623.3M	↑ 14.07%

	Q4 FY23	Q/Q Change
Profit	$656.6M	↑ 5.34%

	Q1 FY24	Q/Q Change
Profit	$561.9M	↓ 14.42%

	Q2 FY24	Q/Q Change
Profit	$626.7M	↑ 11.53%

	Q3 FY24	Q/Q Change
Profit	$593.8M	↓ 5.25%

	FY18	Y/Y Change
Operating Cash Flow	$123.2M	↑ 33.91%
Investing Cash Flow	$-139.8M	↓ 3.19%
Financing Cash Flow	$710.4M	↑ 78.0%

	FY19	Y/Y Change
Operating Cash Flow	$314.5M	↑ 155.28%
Investing Cash Flow	$-1.0B	↑ 626.18%
Financing Cash Flow	$10.7M	↓ 98.49%

	FY20	Y/Y Change
Operating Cash Flow	$475.6M	↑ 51.22%
Investing Cash Flow	$-1.0B	↑ 0.28%
Financing Cash Flow	$912.1M	↑ 8424.3%

	FY21	Y/Y Change
Operating Cash Flow	$442.5M	↓ 6.96%
Investing Cash Flow	$-216.1M	↓ 78.77%
Financing Cash Flow	$10.4M	↓ 98.86%

	FY22	Y/Y Change
Operating Cash Flow	$669.5M	↑ 51.3%
Investing Cash Flow	$-521.5M	↑ 141.32%
Financing Cash Flow	$-552.5M	↓ 5412.5%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$190.3M	↑ 22.46%
Investing Cash Flow	$-555.9M	↑ 197.75%
Financing Cash Flow	$939.5M	↑ 8288.39%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$269.2M	↑ 41.46%
Investing Cash Flow	$-179.5M	↓ 67.71%
Financing Cash Flow	$-637.4M	↓ 167.84%

Dexcom Technicals Summary

Sell

Neutral

Buy

Dexcom is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Dexcom (DXCM) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Dexcom, Inc.	10.61%	19.88%	-28.22%	-20.28%	46.49%
Medtronic Plc	13.21%	13.06%	3.64%	-12.14%	-23.03%
Edwards Lifesciences Corp.	-0.19%	19.36%	-15.84%	-35.79%	-1.17%
Boston Scientific Corp.	14.52%	40.3%	59.02%	147.01%	142.39%
Stryker Corporation	9.08%	23.85%	14.4%	53.77%	84.88%
Abbott Laboratories	12.77%	17.77%	14.11%	-1.62%	46.94%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Dexcom, Inc.	52.62	52.62	1.37	1.69	0.32	0.06	NA	5.07
Medtronic Plc	28.13	28.13	1.56	5.45	0.08	0.04	0.03	38.29
Edwards Lifesciences Corp.	28.3	28.3	6.72	2.55	0.19	0.11	NA	16.18
Boston Scientific Corp.	85.16	85.16	1.86	2.46	0.09	0.05	NA	14.05
Stryker Corporation	50.25	50.25	2.73	13.51	0.19	0.07	0.01	52.86
Abbott Laboratories	16.74	16.74	2.32	5.15	0.15	0.06	0.02	22.94

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Dexcom, Inc.	Buy	$33.9B	46.49%	52.62	17.22%
Medtronic Plc	Buy	$118.0B	-23.03%	28.13	12.06%
Edwards Lifesciences Corp.	Buy	$43.2B	-1.17%	28.3	65.86%
Boston Scientific Corp.	Buy	$151.9B	142.39%	85.16	11.26%
Stryker Corporation	Buy	$148.8B	84.88%	50.25	16.34%
Abbott Laboratories	Buy	$221.9B	46.94%	16.74	13.99%

About Dexcom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Organization	Dexcom
Employees	9500
CEO	Mr. Kevin Ronald Sayer
Industry	Health Technology

Management People of Dexcom

Name	Title
Mr. Kevin Ronald Sayer	Executive Chairman, CEO & President
Mr. Jereme M. Sylvain CPA	Executive VP, CFO & Chief Accounting Officer
Mr. Jacob Steven Leach	Executive VP & COO
Mr. Michael Jon Brown	Executive VP & Chief Legal Officer
Mr. Girish Naganathan	Executive VP & CTO
Mr. Sean Christensen	Director of Corporate Affairs & Head of Investor Relations
Mr. Matthew Dolan	Executive Vice President of Strategy, Corporate Development & Dexcom Labs
Ms. Leverne Marsh	Executive Vice President of Marketing
Ms. Sadie M. Stern	Executive VP & Chief Human Resources Officer
Mr. Donald M. Abbey	Executive Vice President of Global Business Services, Quality & Regulatory Affairs

Important FAQs about investing in DXCM Stock from India :

What is Dexcom share price today?

Dexcom share price today stands at $86.83, Open: $86.87 ; Previous Close: $87.62 ; High: $88.16 ; Low: $86.59 ; 52 Week High: $142.00 ; 52 Week Low: $62.34.

The stock opens at $86.87, after a previous close of $87.62. The stock reached a daily high of $88.16 and a low of $86.59, with a 52-week high of $142.00 and a 52-week low of $62.34.

Can Indians buy Dexcom shares?

Yes, Indians can invest in the Dexcom (DXCM) from India.

With INDmoney, you can buy Dexcom at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Dexcom at zero transaction cost.

How can I buy Dexcom shares from India?

It is very easy to buy Dexcom from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Dexcom (DXCM) be purchased?

Yes, you can buy fractional shares of Dexcom with INDmoney app.

What are the documents required to start investing in Dexcom stocks?

To start investing in Dexcom, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.